Literature DB >> 22008707

Measurement of the minimum apparent diffusion coefficient (ADCmin) of the primary tumor and CA125 are predictive of disease recurrence for patients with endometrial cancer.

Keiichiro Nakamura1, Noriaki Imafuku, Takeshi Nishida, Ieyasu Niwa, Ikuo Joja, Atsushi Hongo, Junichi Kodama, Yuji Hiramatsu.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate whether preoperative measurements of the minimum apparent diffusion coefficient (ADCmin) on magnetic resonance imaging (MRI) and the tumor marker CA125 are correlated with the clinical characteristics and prognosis of patients with endometrial cancer.
METHODS: The distribution of cases that scored positive for each of the biological parameters examined and the correlations with the ADCmin of the primary tumor and the serum tumor marker CA125 were examined for 111 patients with preoperative assessment of primary endometrial cancer.
RESULTS: There were significant correlations between the ADCmin of the primary tumor and the FIGO stage (P=0.001), depth of myometrial invasion (P<0.001), cervical involvement (P=0.003), lymph node metastasis (P=0.027), ovarian metastasis (P<0.001), peritoneal cytology (P=0.027) and tumor maximum size (P<0.001). The disease-free survival (DFS) rate of patients with high serum CA125 was significantly lower than that of patients with low serum CA125 (P=0.0395). The DFS rate of patients with a low ADCmin of the primary tumor was significantly lower than that of patients with a high ADCmin of the primary tumor (P<0.001). In particular, the ADCmin of the primary tumor was an independent factor for disease recurrence in a multivariate analysis (P=0.019).
CONCLUSIONS: The present findings indicate that a low preoperative ADCmin of the primary tumor is an important predictive factor for identifying endometrial cancer patients with a risk of disease recurrence.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22008707     DOI: 10.1016/j.ygyno.2011.10.014

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  20 in total

1.  Quantitative assessment of diffusion kurtosis imaging depicting deep myometrial invasion: a comparative analysis with diffusion-weighted imaging.

Authors:  Jia-Cheng Song; Shan-Shan Lu; Jing Zhang; Xi-Sheng Liu; Cheng-Yan Luo; Ting Chen
Journal:  Diagn Interv Radiol       Date:  2020-03       Impact factor: 2.630

Review 2.  Functional MRI and CT biomarkers in oncology.

Authors:  J M Winfield; G S Payne; N M deSouza
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-13       Impact factor: 9.236

3.  Endometrial Cancer: Combined MR Volumetry and Diffusion-weighted Imaging for Assessment of Myometrial and Lymphovascular Invasion and Tumor Grade.

Authors:  Stephanie Nougaret; Caroline Reinhold; Shaza S Alsharif; Helen Addley; Jocelyne Arceneau; Nicolas Molinari; Boris Guiu; Evis Sala
Journal:  Radiology       Date:  2015-04-30       Impact factor: 11.105

4.  Role of MRI in diagnosing the primary site of origin in indeterminate cases of uterocervical carcinomas: a systematic review and meta-analysis.

Authors:  Pooja Jain; Ankita Aggarwal; Rohini Gupta Ghasi; Amita Malik; Ritu Nair Misra; Kanwaljeet Garg
Journal:  Br J Radiol       Date:  2021-10-28       Impact factor: 3.039

5.  Preoperative prediction of deep myometrial invasion and tumor grade for stage I endometrioid adenocarcinoma: a simple method of measurement on DWI.

Authors:  Bin Yan; Xiufen Liang; Tingting Zhao; Chen Niu; Caixia Ding; Wenjun Liu
Journal:  Eur Radiol       Date:  2018-07-23       Impact factor: 5.315

6.  MUC16 mutations improve patients' prognosis by enhancing the infiltration and antitumor immunity of cytotoxic T lymphocytes in the endometrial cancer microenvironment.

Authors:  Jing Hu; Jing Sun
Journal:  Oncoimmunology       Date:  2018-08-06       Impact factor: 8.110

7.  The preoperative SUVmax is superior to ADCmin of the primary tumour as a predictor of disease recurrence and survival in patients with endometrial cancer.

Authors:  Keiichiro Nakamura; Ikuo Joja; Chikako Fukushima; Tomoko Haruma; Chiaki Hayashi; Tomoyuki Kusumoto; Noriko Seki; Atsushi Hongo; Yuji Hiramatsu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-12       Impact factor: 9.236

Review 8.  What's New in Imaging for Gynecologic Cancer?

Authors:  Sairah R Khan; Mubarik Arshad; Kathryn Wallitt; Victoria Stewart; Nishat Bharwani; Tara D Barwick
Journal:  Curr Oncol Rep       Date:  2017-11-06       Impact factor: 5.075

Review 9.  Endometrial Cancer MRI staging: Updated Guidelines of the European Society of Urogenital Radiology.

Authors:  Stephanie Nougaret; Mariana Horta; Evis Sala; Yulia Lakhman; Isabelle Thomassin-Naggara; Aki Kido; Gabriele Masselli; Nishat Bharwani; Elizabeth Sadowski; Andrea Ertmer; Milagros Otero-Garcia; Rahel A Kubik-Huch; Teresa M Cunha; Andrea Rockall; Rosemarie Forstner
Journal:  Eur Radiol       Date:  2018-07-11       Impact factor: 5.315

Review 10.  Usefulness of DWI in preoperative assessment of deep myometrial invasion in patients with endometrial carcinoma: a systematic review and meta-analysis.

Authors:  Sushant K Das; Xiang K Niu; Jing L Wang; Li C Zeng; Wen X Wang; Anup Bhetuwal; Han F Yang
Journal:  Cancer Imaging       Date:  2014-11-12       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.